Key Takeaways
- A registry entry is a public study record, not a recommendation, treatment offer or proof that a site currently has a place available.
- Search more than one source: the Chinese Clinical Trial Registry, China’s drug-trial information platform, ClinicalTrials.gov and the WHO ICTRP can contain different records.[1][2]
- Search with the diagnosis, subtype, stage, biomarker and city; a broad phrase such as “advanced cancer trial China” produces too much noise.
- Only the study team can determine eligibility after reviewing the complete case. Matching a few online criteria is not enrollment.
- Before traveling, confirm site-level recruitment, required tests, language support, costs, follow-up and who handles complications.
Content
Patients often arrive at a clinical-trial search with a drug name they saw online. That can be a starting point, but it is rarely enough. The same drug may be studied in different diseases, treatment lines, combinations and phases, and a trial shown as “recruiting” globally may not be open at the Chinese site the patient can reach.
The practical task is to create a short list of plausible studies, then let the study sites perform prescreening. Registries help you find and compare records. They do not enroll patients or decide whether the experimental intervention is better than standard care.
Start With a Search Profile
Write down the information that changes eligibility:
- Exact diagnosis and pathology subtype
- Stage, measurable disease and current sites of disease
- Relevant biomarkers and the test method
- Previous treatments, dates, best response and reason each stopped
- Major organ-function issues, infections or autoimmune disease
- Current medicines and functional status
- Cities the patient can realistically reach
Use both the common disease name and a more specific term. For example, search “non-small cell lung cancer,” then add the mutation, treatment line or histology if relevant. Avoid copying an unconfirmed biomarker from a summary; use the laboratory report.
Four Places to Search
The Chinese Clinical Trial Registry (ChiCTR) is listed by WHO as a Primary Registry and displays the WHO trial-registration data set.[1] It includes more than drug trials and can be useful for academic, procedural and other clinical research.
China’s Drug Clinical Trial Registration and Information Disclosure Platform is the relevant public platform for drug trials registered under the National Medical Products Administration process. The NMPA service page explains that trials conducted in China under the applicable drug-trial authorization process are registered and publicly disclosed through the platform.[2]
ClinicalTrials.gov contains study records from many countries and allows filtering by condition, location and recruitment status. Its patient guidance makes an important distinction: people cannot enroll through the website; they use the record to contact the study team.[3]
The WHO International Clinical Trials Registry Platform search portal brings together records from data providers, including ChiCTR and ClinicalTrials.gov.[4] Because the same study can have more than one identifier or appear in more than one source, compare sponsor, protocol number, intervention and sites before assuming two records are different trials.
Read the Record Beyond the Title
Open the full record and note the registry ID, sponsor, last update, study type, phase, intervention, comparator, recruitment status, inclusion and exclusion criteria, sites and contact details. Check the individual Chinese facility, not only the overall study status.
ClinicalTrials.gov explains that a record can show the overall study as recruiting when at least one site is open, and that an “unknown” status can reflect information that has not been verified recently.[5] A site may also have paused screening, filled a cohort or stopped accepting international patients before the public record is updated.
The phase does not tell you whether a treatment is suitable for one person. Early-phase studies often focus heavily on dose and safety; later-phase studies may compare an intervention with an established approach. Participants may or may not receive personal benefit, and researchers may not yet know whether the intervention is better, worse or similar to regular care.[6]
Contact the Site With One Clear Message
Use the registry ID in the subject line and identify the specific hospital site. In a short message, provide the diagnosis, stage, key biomarker, previous treatment, current condition, country of residence and the question: is this site actively prescreening for this cohort?
Ask what records are required, whether remote prescreening is possible, who reviews the file and how long an initial reply usually takes. Do not send an entire unfiltered medical archive in the first email. A one-page summary plus the pathology, biomarker and latest imaging reports is usually a more workable start; the site can request DICOM files or additional documents.
Verify whether communication and consent can be supported in a language the patient understands. Ask whether the site accepts people who live abroad and whether repeated visits, long stays or local follow-up are required.
Prescreening Is Not Enrollment
Prescreening may rely on records and can identify obvious mismatches. Formal screening may require examination, laboratory tests, new imaging, pathology review or a washout period after previous treatment. A patient is not enrolled until the study team confirms eligibility and the consent and enrollment process is completed.
China’s Good Clinical Practice rules state that participants’ rights and safety take priority over scientific and social benefit, and identify ethics review and informed consent as core protections.[7] Read the complete consent document. Ask about the purpose of the study, alternatives, randomization, placebo or control treatment, foreseeable risks, contraception requirements, privacy, injury arrangements, withdrawal and what happens after participation ends.
Joining must be voluntary. The patient should have time to ask questions and should not be pressured to sign before understanding the study.
Costs, Travel and Treatment Continuity
“The study drug is provided” does not mean every cost is covered. Ask separately about trial-required tests, standard-care medicines, hospital admission, treatment of complications, interpretation, accommodation, repeated travel and care after leaving China. Obtain the answer in writing from the site or sponsor.
Do not stop effective treatment, begin a washout period or book nonrefundable travel because an intermediary says the patient “looks eligible.” Those decisions require the study investigator and the treating clinician to review the case and the protocol.
Keep the home oncologist involved. If the patient is not eligible, withdraws or the study ends, someone still needs to manage the disease, prescriptions and adverse effects.
Warning Signs
Be cautious when a person cannot provide a registry identifier or protocol number; guarantees enrollment or benefit; asks for payment to “reserve” a trial place; discourages discussion with the current doctor; will not name the institution and principal investigator; or presents an unapproved commercial treatment as if it were a registered clinical trial.
A real registry number does not prove that every claim made by an intermediary is accurate. Verify the site and contact through the registry or the hospital’s official channel.
Medical disclaimer: This guide explains how to search for and verify clinical trials. It does not determine eligibility or recommend an experimental treatment. Trial status, sites and criteria change; confirm all details directly with the study team and discuss the decision with a qualified clinician.
Related Hospitals
Use the facility listed in the current registry record and verify it through the hospital’s official clinical-research or department contact. A hospital may run some trials but not the specific protocol being considered.
Related Treatments
Registration does not mean an investigational product is approved or proven effective. Standard care, other trials and supportive care should remain part of the discussion.
Related Guides
- Understanding Clinical Trial Phases
- Clinical Trial Eligibility: Why Patients Who Look Similar May Qualify Differently
- Questions to Ask Before Joining a Clinical Trial in China
- What Happens After a Clinical Trial Ends?
FAQ
Which registry should I search first?
Start with the source most likely to cover the study type, but search at least two. ChiCTR and WHO ICTRP cover a broad range; the Chinese drug-trial platform is important for drug studies; ClinicalTrials.gov may list multinational protocols with Chinese sites.
Does “recruiting” mean the hospital in China is accepting patients now?
Not necessarily. Overall status may be driven by another site, and public records can lag. Contact the individual facility and quote the registry ID.[5]
Can I know from the online criteria whether I qualify?
You can identify obvious mismatches, but only the study team can decide after reviewing all inclusion and exclusion criteria and completing required screening.
Are clinical trials free?
Not automatically. The sponsor may cover the investigational product and protocol-required procedures, while standard care, travel, lodging or complication care may be handled differently. Ask for a written breakdown.
Can an agent guarantee a place in a trial?
No legitimate intermediary can override the protocol or the investigator’s eligibility decision. A guaranteed place or guaranteed benefit is a serious warning sign.
Sources
- World Health Organization: Chinese Clinical Trial Registry Profile
- National Medical Products Administration: Drug Clinical Trial Registration Service
- ClinicalTrials.gov: How to Join a Study
- World Health Organization: ICTRP Data Providers
- ClinicalTrials.gov: Protocol Registration Definitions
- ClinicalTrials.gov: Learn About Studies
- State Council Gazette: Good Clinical Practice for Drug Trials (2020)
Hero Image Prompt
Use case: photorealistic-natural. Asset type: 16:9 website hero. A patient and bilingual clinical-research coordinator seated side by side in a hospital research office, comparing a de-identified trial registry page on a laptop with a concise paper screening checklist. A clinician is visible in the background reviewing a chart. Documentary editorial photography, natural light, focused expressions, realistic modern Chinese hospital. No readable text, logos, flags, patient identifiers, medication branding, needles, promises of benefit or futuristic interfaces.